2013
Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects
Liang E, Garzone P, Cedarbaum JM, Koller M, Tran T, Xu V, Ross B, Jhee SS, Ereshefsky L, Pastrak A, Abushakra S. Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects. Clinical Pharmacology In Drug Development 2013, 2: 186-194. PMID: 27121673, DOI: 10.1002/cpdd.14.Peer-Reviewed Original ResearchAverage trough concentrationCerebrospinal fluidAlzheimer's diseaseTrough concentrationsDay 8Magnetic resonance spectroscopy scansCSF drug levelsHealthy young subjectsPredetermined time pointsOral treatmentCSF levelsAmyloid-beta fragmentsCSF concentrationsPlasma levelsDrug levelsHealthy subjectsAmyloid betaCSF samplesPharmacokinetic profileYoung subjectsTransgenic modelBaseline levelsTime pointsWhite matter voxelsAβ fragments
1992
Clinical and Pharmacokinetic Aspects of High Dose Oral Baclofen Therapy
Aisen M, Dietz M, Rossi P, Cedarbaum J, Kutt H. Clinical and Pharmacokinetic Aspects of High Dose Oral Baclofen Therapy. Journal Of Spinal Cord Medicine 1992, 15: 211-216. PMID: 1431867, DOI: 10.1080/01952307.1992.11761520.Peer-Reviewed Original ResearchConceptsHigh-dose baclofenDesk ReferenceAdequate symptomatic reliefDosage of baclofenPotential renal insufficiencyTreatment of spasticityPattern of prescriptionPeak plasma levelsPhysicians' Desk ReferenceBaclofen levelsBaclofen therapyNeurogenic bladderRenal insufficiencySymptomatic reliefBlood levelsMuscle relaxantsPlasma levelsPharmacokinetic aspectsRenal clearanceClinical practiceBaclofenPatientsPilot studyPrior reportsUseful role